Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity
E Bartolini, E Borgogni, M Bruttini, A Muzzi, M Giuliani, S Iozzi, R Petracca, M Martinelli, S Bonacci, S Marchi, C Brettoni, C Donati, G Torricelli, S Guidotti, M Domina, C Beninati, G Teti, F Felici, R Rappuoli, F Castellino, G Del Giudice, V Masignani, M Pizza, D Maione, E Bartolini, E Borgogni, M Bruttini, A Muzzi, M Giuliani, S Iozzi, R Petracca, M Martinelli, S Bonacci, S Marchi, C Brettoni, C Donati, G Torricelli, S Guidotti, M Domina, C Beninati, G Teti, F Felici, R Rappuoli, F Castellino, G Del Giudice, V Masignani, M Pizza, D Maione
Abstract
Serogroup B meningococcus (MenB) is a leading cause of meningitis and sepsis across the world and vaccination is the most effective way to protect against this disease. 4CMenB is a multi-component vaccine against MenB, which is now licensed for use in subjects >2 months of age in several countries. In this study, we describe the development and use of an ad hoc protein microarray to study the immune response induced by the three major 4CMenB antigenic components (fHbp, NHBA and NadA) in individual sera from vaccinated infants, adolescents and adults. The resulting 4CMenB protein antigen fingerprinting allowed the identification of specific human antibody repertoire correlating with the bactericidal response elicited in each subject. This work represents an example of epitope mapping of the immune response induced by a multicomponent vaccine in different age groups with the identification of protective signatures. It shows the high flexibility of this microarray based methodology in terms of high-throughput information and minimal volume of biological samples needed.
Trial registration: ClinicalTrials.gov NCT00560313 NCT00661713 NCT00944034.
Conflict of interest statement
This study was sponsored by Novartis Vaccines, now acquired by the GSK group of companies. All authors have declared the following interests: E. Ba, E. Bo, A.M., M.G., S.I., R.P., M.M., S.B., S.M., C. Br, C.D., G. To, S.G., R.R., F.C., G.D.G., V.M., M.P. and D.M. were permanent employees of Novartis Vaccines at the time of the study. M.B. was holding a PhD studentship and collaborated with GSK at the time of the study as part of his PhD training. Following the acquisition of Novartis Vaccines by the GSK group of companies in March, 2015, E. Ba, E. Bo, A.M., M.G., S.I., R.P., S.B., S.M., C. Br, G. To, S.G., R.R., G.D.G., V.M., M.P. and D.M. are now permanent employees of the GSK group of companies. M.B. is now permanent employee of Polo GGB. C.D. is now permanent employee of Fondazione Edmund Mach, San Michele all’Adige. C. Be and G. Te are Professors, and M.D. was holding a PhD studentship at the time of the study, at the University of Messina. F.F. is Professor at the University of Molise. F.C. is now permanent employee of US Department of Health & Human services. G.D.G. own shares and stock options of the GSK group of companies.
Figures
References
- Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19:2688. doi: 10.1016/S0264-410X(00)00554-5.
- Pizza M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816. doi: 10.1126/science.287.5459.1816.
- Toneatto D, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum. Vaccines. 2011;7(Jun):646. doi: 10.4161/hv.7.6.15482.
- Giuliani MM, et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA. 2006;103:10834. doi: 10.1073/pnas.0603940103.
- van Alphen L, van den Dobbelsteen G. Meningococcal B vaccine development and evaluation of efficacy. Hum. Vaccines. 2008;4:158. doi: 10.4161/hv.4.2.4871.
- Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222. doi: 10.1016/j.vaccine.2005.01.051.
- Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 2009;9:185. doi: 10.1038/nri2508.
- Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 2004;4:553. doi: 10.1038/nri1394.
- Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol. Immunol. 2009;46:2419. doi: 10.1016/j.molimm.2009.04.009.
- Cho HS, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756. doi: 10.1038/nature01392.
- Rosen O, Anglister J. Epitope mapping of antibody-antigen complexes by nuclear magnetic resonance spectroscopy. Methods Mol. Biol. 2009;524:37. doi: 10.1007/978-1-59745-450-6_3.
- Hoyer W, Gronwall C, Jonsson A, Stahl S, Hard T. Stabilization of a beta-hairpin in monomeric Alzheimer’s amyloid-beta peptide inhibits amyloid formation. Proc. Natl Acad. Sci. USA. 2008;105:5099. doi: 10.1073/pnas.0711731105.
- Malito E, et al. Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc. Natl Acad. Sci. USA. 2013;110:3304. doi: 10.1073/pnas.1222845110.
- Faleri A, et al. Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties. FASEB J. 2014;28:1644. doi: 10.1096/fj.13-239012.
- Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315. doi: 10.1126/science.4001944.
- Minenkova O, et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int. J. Cancer. 2003;106:534. doi: 10.1002/ijc.11269.
- Beghetto E, Gargano N. Lambda-display: a powerful tool for antigen discovery. Molecules. 2011;16:3089. doi: 10.3390/molecules16043089.
- Beghetto E, et al. Discovery of novel Streptococcus pneumoniae antigens by screening a whole-genome lambda-display library. FEMS Microbiol. Lett. 2006;262:14. doi: 10.1111/j.1574-6968.2006.00360.x.
- Kazim AL, Atassi MZ. Haemoglobin binding with haptoglobin. Localization of the haptoglobin-binding site on the alpha-chain of human haemoglobin. Biochem. J. 1981;197:507. doi: 10.1042/bj1970507.
- Negm OH, et al. Profiling humoral immune responses to clostridium difficile-specific antigens by protein microarray analysis. Clin. Vacc. Immunol. 2015;22:1033–1039. doi: 10.1128/CVI.00190-15.
- Neuman de Vegvar HE, et al. Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen. J. Virol. 2003;77:11125. doi: 10.1128/JVI.77.20.11125-11138.2003.
- Price JV, et al. On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat. Med. 2012;18:1434. doi: 10.1038/nm.2913.
- Hueber W, et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2005;52:2645. doi: 10.1002/art.21269.
- Robinson WH, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 2002;8:295. doi: 10.1038/nm0302-295.
- Lee SJ, et al. Identification of a common immune signature in murine and human systemic Salmonellosis. Proc. Natl Acad. Sci. USA. 2012;109:4998. doi: 10.1073/pnas.1111413109.
- Rigat F, et al. Retrospective identification of a Broad IgG repertoire differentiating patients with S. aureus skin and soft tissue infections from controls. Front. Immunol. 2019;10:114. doi: 10.3389/fimmu.2019.00114.
- Awanye AM, et al. Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis. Sci. Rep. 2019;9:6843. doi: 10.1038/s41598-019-43139-0.
- Davies DH, et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J. Virol. 2008;82:652. doi: 10.1128/JVI.01706-07.
- Price JV, et al. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays. PLoS ONE. 2013;8:e64555. doi: 10.1371/journal.pone.0064555.
- Steller S, et al. Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections. Proteomics. 2005;5:2048. doi: 10.1002/pmic.200401097.
- Legutki JB, Johnston SA. Immunosignatures can predict vaccine efficacy. Proc. Natl Acad. Sci. USA. 2013;110:18614. doi: 10.1073/pnas.1309390110.
- Domina M, et al. Functional characterization of a monoclonal antibody epitope using a lambda phage display-deep sequencing platform. Sci. Rep. 2016;6:31458. doi: 10.1038/srep31458.
- Schneider MC, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458:890. doi: 10.1038/nature07769.
- Tavano R, et al. Mapping of the Neisseria meningitidis NadA cell-binding site: relevance of predicted {alpha}-helices in the NH2-terminal and dimeric coiled-coil regions. J. Bacteriol. 2011;193:107. doi: 10.1128/JB.00430-10.
- Malito E, et al. Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proc. Natl Acad. Sci. USA. 2014;111:17128. doi: 10.1073/pnas.1419686111.
- Esposito V, et al. Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis. J. Biol. Chem. 2011;286:41767. doi: 10.1074/jbc.M111.289314.
- Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30:B87. doi: 10.1016/j.vaccine.2012.01.033.
- Bertoldi I, et al. Exploiting chimeric human antibodies to characterize a protective epitope of Neisseria adhesin A, one of the Bexsero vaccine components. FASEB J. 2016;30:93–101. doi: 10.1096/fj.15-273813.
- Domina M, et al. Epitope mapping of a monoclonal antibody directed against neisserial heparin binding antigen using next generation sequencing of antigen-specific libraries. PLoS ONE. 2016;11:e0160702. doi: 10.1371/journal.pone.0160702.
- Giuliani M, et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci. Rep. 2018;8:3700. doi: 10.1038/s41598-018-22057-7.
- Bombaci M, et al. Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens. PLoS ONE. 2009;4(Jul):e6332. doi: 10.1371/journal.pone.0006332.
- O’Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74:15. doi: 10.1007/s40265-013-0155-7.
- Santolaya ME, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617. doi: 10.1016/S0140-6736(11)61713-3.
- Snape MD, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. Can. Med. Assoc. J. 2013;185:E715. doi: 10.1503/cmaj.130257.
- Snape MD, et al. Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age. Pediatr. Infect. Dis. J. 2016;35:e113. doi: 10.1097/INF.0000000000001056.
- Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin. Vaccin. Immunol. 2011;18:483. doi: 10.1128/CVI.00304-10.
- Bambini S, et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine. 2009;27:2794. doi: 10.1016/j.vaccine.2009.02.098.
- Muzzi A, Mora M, Pizza M, Rappuoli R, Donati C. Conservation of meningococcal antigens in the genus Neisseria. MBio. 2013;4:e00163. doi: 10.1128/mBio.00163-13.
- Jacobsson S, et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine. 2006;24:2161. doi: 10.1016/j.vaccine.2005.11.006.
- Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 1969;129:1327. doi: 10.1084/jem.129.6.1327.
- Masignani V, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 2003;197:789. doi: 10.1084/jem.20021911.
- Fletcher LD, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 2004;72:2088. doi: 10.1128/IAI.72.4.2088-2100.2004.
- Gossger N, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. J. Am. Med. Assoc. 2012;307:573. doi: 10.1001/jama.2012.85.
- Cariccio VL, et al. Phage display revisited: Epitope mapping of a monoclonal antibody directed against Neisseria meningitidis adhesin A using the PROFILER technology. MAbs. 2016;8:741. doi: 10.1080/19420862.2016.1158371.
- Domina M, et al. Rapid profiling of the antigen regions recognized by serum antibodies using massively parallel sequencing of antigen-specific libraries. PLoS ONE. 2014;9:e114159. doi: 10.1371/journal.pone.0114159.
- Klock HE, Lesley SA. The Polymerase Incomplete Primer Extension (PIPE) method applied to high-throughput cloning and site-directed mutagenesis. Methods Mol. Biol. 2009;498:91. doi: 10.1007/978-1-59745-196-3_6.
Source: PubMed